Our publications

Preliminary evaluation of 64Cu-ATSM as a tracer of predictive assessment of neoadjuvant treatment response in locally advanced rectal cancer OP-0062.
Colombié M, Ferrer L , Lacombe M, Fleury V, le Thiec M, Morel A, Maugerat B, Rusu D, Varmenot N, Tremolieres P, Allam N, Rio E, Guimas V, Masson I, Senellart H, Hiret S, Salaun PY, Campion L, Vidal A, Haddad F, Rauscher A, Kraeber-Bodéré F, Bourgeois M, Rousseau C
EANM’21 34th Annual congress of the European Association of Nuclear Medicine, virtual edition, October 20-23 2021

Evaluation théranostique d’un anticorps radiomarqué au cuivre-64 dans un modèle murin de myélome multiple.
Métivier C, Le Saëc P, Marionneau-Lambot S, Chauvet C, Hofgaard PO, Bogen B, Gaschet J, Tripier R, Haddad F, Chérel M, Chouin N, Faivre-Chauvet A, Rbah-Vidal L
15èmes Journées annuelles du Cancéropôle Grand-Ouest, Angers, France, July 1-2 2021

Theranostic evaluation of a copper-64 radiolabelled antibody in a mouse model of multiple myeloma
Métivier C, Le Saëc P, Marionneau-Lambot S, Chauvet C, Hofgaard PO, Bogen B, Gaschet J, Tripier R, Haddad F, Chérel M, Chouin N, Faivre-Chauvet A, Rbah-Vidal L
14th Workshop Adaptation of the tumour and its ecosystem to radiotherapies, Le Bono, France, September 22-25 2021

In vivo theranostic evaluation of a 64Cu-radiolabelled antibody in a murine model of multiple myeloma
Métivier C, Remaud-Le Saëc P, Marionneau-Lambot S, Davodeau F, Chauvet C, Saï-Maurel C, Hofgaard PO, Bogen B, Tripier R, Haddad F, Gaschet J, Chérel M, Chouin N, Faivre-Chauvet A, Rbah-Vidal L
14th Workshop Adaptation of the tumour and its ecosystem to radiotherapies, Le Bono, France, September 22-25 2021

Interest of whole-body immuno-SPECT-CT for canine diffuse large B-cell lymphoma (DLBCL) staging before radioimmunotherapy (RIT) using an anti-CD22 monoclonal antibody
Etienne F, Nguyen F, Becavin S, Bodet-Milin C, Bourgeois M, Vidal A, Abadie J, Bouhsina N, Davodeau F, Ibisch C, Chouin N
European Society of Veterinary Oncology (ESVONC) Conference, virtual edition, May 28-29 2021

Promising Clinical Performance of Pretargeted Immuno-PET with Anti-CEA Bispecific Antibody and Gallium-68-Labelled IMP-288 Peptide for Imaging Colorectal Cancer Metastases: A Pilot Study, Touchefeu, Y.; Bailly, C.; Frampas, E.; Eugène, T.; Rousseau, C.; Bourgeois, M.; Bossard, C.; Faivre-Chauvet, A.; Rauscher, A.; Masson, D.; David, A.; Cerato, E.; Carlier, T.; Sharkey, R. M.; Goldenberg, D. M.; Barbet, J.; Kraeber-Bodere, F.; Bodet-Milin, C., Eur J Nucl Med Mol Imaging 2021, 48 (3), 874–882. doi:10.1007/s00259-020-04989-3

Anti-CEA Pretargeted Immuno-PET Shows Higher Sensitivity Than DOPA PET/CT in Detecting Relapsing Metastatic Medullary Thyroid Carcinoma: Post Hoc Analysis of the IPET-MTC Study, Bodet-Milin, C.; Faivre-Chauvet, A.; Carlier, T.; Ansquer, C.; Rauscher, A.; Frampas, E.; Toulgoat, F.; Masson, D.; Bourgeois, M.; Cerato, E.; Rohmer, V.; Couturier, O.; Drui, D.; Goldenberg, D. M.; Sharkey, R. M.; Barbet, J.; Kraeber-Bodere, F., J Nucl Med 2021, 62 (9), 1221–1227. doi:10.2967/jnumed.120.252791

 Copper-64-Labeled 1C1m-Fc, a New Tool for TEM-1 PET Imaging and Prediction of Lutetium-177-Labeled 1C1m-Fc Therapy Efficacy and Safety, Delage JA, Gnesin S, Prior JO, Barbet J, Le Saëc P, Marionneau-Lambot S, Gouard S, Chérel M, Bourgeois M, Schaefer N, Viertl D, Fierle JK, Dunn SM, Faivre-Chauvet A. Cancers (Basel). 2021 Nov 25;13(23):5936.
doi:10.3390/cancers13235936

Impact of DOTA Conjugation on Pharmacokinetics and Immunoreactivity of [177Lu]Lu-1C1m-Fc, an Anti TEM-1 Fusion Protein Antibody in a TEM-1 Positive Tumor Mouse Model, Delage JA, Faivre-Chauvet A, Barbet J, Fierle JK, Schaefer N, Coukos G, Viertl D, Dunn SM, Gnesin S, Prior JO, Pharmaceutics, 2021 Jan 13;13(1):96. doi: 10.3390/pharmaceutics13010096

Cell Tracking in Cancer Immunotherapy, Perrin J, Capitao M, Mougin-Degraef M, Guérard F, Faivre-Chauvet A, Rbah-Vidal L, et al, Front Med. 14 févr 2020;7:34. https://doi.org/10.3389/fmed.2020.00034